COSMOS Pharmaceutical Corporation
3349.T · JPX
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -3.97 | 2.23 | 0.68 | -1.02 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 38.48 | 45.27 | 32.37 | 40.36 |
| Quality | ||||
| ROIC | 2.51% | 2.64% | 2.66% | 2.11% |
| Gross Margin | 20.99% | 20.87% | 21.57% | 21.10% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 5.79% | 6.91% | 7.66% | 8.05% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.45 | -0.46 | 0.33 | -0.95 |
| Interest Coverage | 105.87 | 80.51 | 235.08 | 182.58 |
| Efficiency | ||||
| Inventory Turnover | 2.41 | 2.22 | 2.19 | 2.05 |
| Cash Conversion Cycle | -37.30 | -32.97 | -31.79 | -37.18 |